Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 26, Issue 21, pp. 5598-5608
PubMed
Published By
Print ISSN
Online ISSN
History
- Received April 15, 2020
- Revision received July 3, 2020
- Accepted August 14, 2020
- Published first August 18, 2020.
Article Versions
- Previous version (August 18, 2020 - 06:20).
- Previous version (September 24, 2020 - 06:27).
- You are viewing the most recent version of this article.
Copyright & Usage
©2020 American Association for Cancer Research.
Author Information
- Jean-François Martini1,
- Elizabeth R. Plimack2,*,
- Toni K. Choueiri3,
- David F. McDermott4,
- Igor Puzanov5,6,
- Mayer N. Fishman7,
- Daniel C. Cho8,
- Ulka Vaishampayan9,
- Bradley Rosbrook1,
- Kathrine C. Fernandez10,
- Jamal C. Tarazi1,
- Saby George6, and
- Michael B. Atkins11
- 1Pfizer Global Product Development–Oncology, San Diego, California.
- 2Fox Chase Cancer Center, Philadelphia, Pennsylvania.
- 3Dana-Farber Cancer Institute, Boston, Massachusetts.
- 4Beth Israel Deaconess Medical Center, Boston, Massachusetts.
- 5Vanderbilt University Medical Center, Nashville, Tennessee.
- 6Roswell Park Comprehensive Cancer Center, Buffalo, New York.
- 7Moffitt Cancer Center, Tampa, Florida.
- 8Perlmutter Cancer Center at NYU Langone Medical Center, New York, New York.
- 9Karmanos Cancer Institute, Wayne State University, Detroit, Michigan.
- 10Pfizer Global Product Development Oncology, Cambridge, Massachusetts.
- 11Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC.
- ↵*Corresponding Author:
Elizabeth R. Plimack, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111-2497. Phone: 215-728-3889; Fax: 215-728-3639; E-mail: elizabeth.plimack{at}fccc.edu
November 2020
Volume 26, Issue 21
Volume 26, Issue 21
Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma
Jump to section
Advertisement